Skin Diseases, Infectious: Clinical Trials

1,546 trials for Skin Diseases, Infectious, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1002 completed, 168 unknown, 135 recruiting, 86 terminated. 405 Phase 2, 317 Phase 3, 287 Not applicable, 176 Phase 1, 131 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 2405Completed 278, Unknown 34, Terminated 27, Recruiting 26, Active not recruiting 13, Withdrawn 13, Not yet recruiting 11, Suspended 2, Enrolling by invitation 1
Phase 3317Completed 220, Unknown 39, Active not recruiting 18, Terminated 17, Recruiting 12, Not yet recruiting 6, Withdrawn 4, Enrolling by invitation 1
Not applicable287Completed 171, Unknown 48, Recruiting 30, Terminated 16, Not yet recruiting 15, Withdrawn 6, Active not recruiting 1
Phase 1176Completed 134, Recruiting 11, Terminated 9, Unknown 7, Withdrawn 6, Not yet recruiting 4, Active not recruiting 2, Enrolling by invitation 2, Suspended 1
Phase 4131Completed 85, Recruiting 12, Terminated 12, Unknown 11, Not yet recruiting 8, Withdrawn 3
Early Phase 121Completed 8, Unknown 4, Withdrawn 4, Recruiting 3, Not yet recruiting 2

Follow Skin Diseases, Infectious: new trials by email Literature Review of Skin Diseases, Infectious trials Research Report on Skin Diseases, Infectious

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients
Vehicle gel, SR-T100 gel with 1.0% of SM, SR-T100 gel with 2.3% of SM - Common Wart
Phase 2SuspendedG&E Herbal Biotechnology Co., LTD1022030-09-012023-09-14
HEALTH Trial - Healthy Adult Evaluation of Ivermectin Bioequivalence: Infant Versus Standard Formulation
ivermectin infant formula preparation, Standard ivermectin 3mg tablet - Scabies
Phase 1SuspendedMurdoch Childrens Research Institute522027-01-012026-10-09
Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)
Sodium Stibogluconate (SSG), Miltefosine, Miltefosine + Paromomycin - Cutaneous Leihmaniasis
Phase 3Not yet recruitingInstitute of Tropical Medicine, Belgium9002027-01-012026-03-10
Immersive Technology Headsets to Reduce Procedural Pain and Anxiety: Feasibility and Effects in Cutaneous Leishmaniasis Patients in Pakistan
Virtual Reality - Cutaneous Leishmaniasis, Pain
Not applicableNot yet recruitingStanford University152027-01-012026-10-05
Platform Trial for Salvage Consolidation Therapy in Dimorphic Fungi
Oteseconazole - Coccidioidomycosis, Blastomycosis
Phase 2Not yet recruitingUniversity of Minnesota302026-12-012026-09-04
A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients
Hidradenitis Suppurativa
Not yet recruitingNovartis Pharmaceuticals1862026-11-132026-10-20
Naproxen Versus Placebo as Adjunct Treatment of Cellulitis
enteric-coated naproxen, Cephalexin Tablets, Placebo - Cellulitis, Skin Disease, Infectious
Phase 3Not yet recruitingOttawa Hospital Research Institute8842026-11-012026-10-20
Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
Olatorepatide, Placebo - Hidradenitis Suppurativa
Phase 2Not yet recruitingRegeneron Pharmaceuticals3002026-10-302026-09-21
A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With Secukinumab
Hidradenitis Suppurativa
Not yet recruitingNovartis Pharmaceuticals342026-10-302026-09-21
Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM
Busulfan, Palifermin, Plerixafor - WHIM, Warts
Phase 1 / Phase 2Enrolling by invitationNational Institute of Allergy and Infectious Diseases (NIAID)102026-10-272026-10-22
A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS
LOU064, Placebo - Hidradenitis Suppurativa
Phase 1RecruitingNovartis Pharmaceuticals302026-10-152026-10-16
Systemic Antifungal Plus Q-Switched Nd:YAG Laser for Onychomycosis
Terbinafine, Q-switched Nd:YAG laser - Onychomycosis
Not applicableNot yet recruitingAssiut University972026-10-102026-10-09
Intralesional Acyclovir Versus Intralesional Zinc Sulphate in the Treatment of Plantar Warts
Intralesional Acyclovir, Intralesional Zinc Sulphate - Warts, Plantar Warts
Phase 3Not yet recruitingAssiut University762026-10-012026-09-29
Moxifloxacin Versus Clindamycin in the Management of Odontogenic Maxillofacial Infectious Processes
Clindamycin, Moxifloxacin (400 mg) - Odontogenic Infection, Maxillofacial Infection
Not applicableNot yet recruitingNishtar Medical University602026-10-012026-10-16
Secondary Bacterial Infections and Nasal Colonization in Scabies and Atopic Dermatitis
Atopic Dermatitis (AD), Scabies
Not yet recruitingIstanbul Medeniyet University512026-10-012026-09-15
Comparison of Itraconazole With Itraconazole and Isotretinoin in the Treatment Duration, Safety a n d Cure Rate in Adult Patients of Tinea Corporis/ Cruris-A Randomised Controlled Trail
Itraconazole (200 mg), ISOtretinoin 20 MG - Tinea Corporis
Phase 4Not yet recruitingPak Emirates Military Hospital602026-10-012026-06-30
Skin-in-Sight: a Longitudinal Cohort Infrastructure for Standardized Remote Monitoring and the Evaluation of Digital Care Innovations in Chronic Skin Diseases
Psoriasis, Eczema/Atopic Dermatitis
Not yet recruitingMedisch Spectrum Twente10002026-10-012026-09-04
Clinical, Dermoscopic, and Mycological Evaluations of Resistant Dermatophytosis
Direct microscopic KOH examination, Culture:, Antifungal susceptibility testing: - Fungal Skin Infection, Tinea Corporis
Not yet recruitingSohag University1002026-10-012026-09-01
Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis Suppurativa
Botulinum Toxin A (Allergan, Inc, Irvine CA), Placebo - Hidradenitis Suppurativa (HS)
Phase 2Not yet recruitingUniversity of Massachusetts, Worcester402026-10-012026-09-10
Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)
VP-102 - Common Warts, Common Warts (Verruca Vulgaris)
Phase 2Not yet recruitingVerrica Pharmaceuticals Inc.302026-10-012026-10-20

Showing 20 of 1546. Sign in to see all of them.

Narrower conditions

Hidradenitis Suppurativa (280)  ·  Herpes Simplex (159)  ·  Cellulitis (157)  ·  Onychomycosis (134)  ·  Warts (121)  ·  Condylomata Acuminata (112)  ·  Leishmaniasis, Cutaneous (102)  ·  Leishmaniasis (71)  ·  Tinea Pedis (69)  ·  Abscess (54)  ·  Herpes Labialis (52)  ·  Scabies (50)  ·  Skin Diseases (47)  ·  Uterine Cervical Neoplasms (45)

Broader conditions

Skin and Connective Tissue Diseases (1543)  ·  Infections (1506)  ·  Skin Diseases (1394)  ·  Bacterial Infections and Mycoses (732)  ·  Pathological Conditions, Signs and Symptoms (468)  ·  DNA Virus Infections (452)  ·  Virus Diseases (447)  ·  Skin Diseases, Viral (446)  ·  Suppuration (443)  ·  Bacterial Infections (428)  ·  Pathologic Processes (380)  ·  Skin Diseases, Bacterial (377)  ·  Dermatomycoses (282)  ·  Mycoses (275)

Interventions

Ivermectin (32)  ·  Acyclovir (31)  ·  Vancomycin (31)  ·  miltefosine (29)  ·  Terbinafine (28)  ·  Valacyclovir (26)  ·  Itraconazole (25)  ·  Meglumine Antimoniate (23)  ·  Linezolid (19)  ·  Cryotherapy (18)  ·  Adalimumab (16)  ·  Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (16)  ·  Permethrin (15)  ·  secukinumab (14)  ·  Azithromycin (13)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (46)  ·  GlaxoSmithKline (34)  ·  Novartis Pharmaceuticals (30)  ·  Merck Sharp & Dohme LLC (24)  ·  Pfizer (23)  ·  Sun Pharmaceutical Industries, Inc. (18)  ·  AbbVie (17)  ·  Assiut University (16)  ·  U.S. Army Medical Research and Development Command (16)  ·  Incyte Corporation (12)  ·  Shanghai Bovax Biotechnology Co., Ltd. (12)  ·  Institute of Tropical Medicine, Belgium (11)  ·  Assistance Publique - Hôpitaux de Paris (10)  ·  Combined Military Hospital Abbottabad (10)  ·  Drugs for Neglected Diseases (10)

Countries

United States (632)  ·  Canada (121)  ·  Germany (110)  ·  France (93)  ·  Spain (79)  ·  China (75)  ·  Poland (62)  ·  United Kingdom (60)  ·  Australia (57)  ·  Brazil (52)  ·  Netherlands (52)  ·  Italy (51)  ·  Belgium (45)  ·  Greece (41)  ·  Pakistan (38)

Top investigators

G. Ralph Corey, MD (6)  ·  Hadar Lev-Tov, MD (5)  ·  Jun Zhang, Master (5)  ·  Connie Celum, MD, MPH (4)  ·  Gary Weil, MD (4)

Results publications

PMID 32184277, PMID 41276263, PMID 19236277, PMID 19236279, PMID 19935017, PMID 27422279, PMID 27518661, PMID 28379954, PMID 29380251, PMID 30597021, PMID 30716446, PMID 30982556, PMID 31604104, PMID 34741280, PMID 34905144, PMID 34922058, PMID 36746171, PMID 41166720, PMID 41248770, PMID 42525209, PMID 15897380, PMID 17845167, PMID 18444791, PMID 19095213, PMID 20346539, PMID 20695801, PMID 20949623, PMID 21115456, PMID 21471141, PMID 21991950, PMID 22236226, PMID 22416054, PMID 22454089, PMID 23066159, PMID 23247938, PMID 23299013, PMID 23336207, PMID 23632723, PMID 23877689, PMID 24897082, PMID 25007364, PMID 25273231, PMID 26343451, PMID 27370913, PMID 27585969, PMID 28630189, PMID 29074187, PMID 29211620, PMID 29214505, PMID 29358292

NIH funding

2023 (10), 2025 (9), 2008 (6), 2018 (6), 2019 (5), 2015 (4), 2004 (3), 2014 (3), 2017 (3), N01AI30025 (3), U19AI065866 (3), 2009 (2), 2016 (2), P01AI030731 (2), I50HX002263 (1)